Nxera Pharma Co., Ltd.
4565.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥6,754,000 | ¥8,450,000 | ¥6,644,000 | ¥6,852,000 |
| % Growth | -20.1% | 27.2% | -3% | – |
| Cost of Goods Sold | ¥2,673,000 | ¥1,858,000 | ¥1,615,000 | ¥2,127,000 |
| Gross Profit | ¥4,081,000 | ¥6,592,000 | ¥5,029,000 | ¥4,725,000 |
| % Margin | 60.4% | 78% | 75.7% | 69% |
| R&D Expenses | ¥3,726,000 | ¥3,666,000 | ¥3,808,000 | ¥3,299,000 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥3,844,000 | ¥3,865,000 | ¥3,701,000 | ¥4,298,000 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥2,238,000 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | -¥295,000 |
| Operating Expenses | ¥7,570,000 | ¥7,531,000 | ¥7,509,000 | ¥7,302,000 |
| Operating Income | -¥3,489,000 | -¥939,000 | -¥2,480,000 | -¥1,683,000 |
| % Margin | -51.7% | -11.1% | -37.3% | -24.6% |
| Other Income/Exp. Net | ¥373,000 | -¥627,000 | ¥324,000 | -¥686,000 |
| Pre-Tax Income | -¥3,116,000 | -¥1,566,000 | -¥2,156,000 | -¥2,369,000 |
| Tax Expense | -¥1,444,000 | ¥811,000 | -¥1,396,000 | -¥1,034,000 |
| Net Income | -¥1,672,000 | -¥2,377,000 | -¥760,000 | -¥1,335,000 |
| % Margin | -24.8% | -28.1% | -11.4% | -19.5% |
| EPS | -18.48 | -26.38 | -8.45 | -14.86 |
| % Growth | 29.9% | -212.2% | 43.1% | – |
| EPS Diluted | -18.48 | -26.38 | -8.45 | -14.85 |
| Weighted Avg Shares Out | 90,495 | 90,105 | 89,901 | 89,860 |
| Weighted Avg Shares Out Dil | 90,495 | 90,105 | 89,901 | 89,901 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥239,000 | ¥255,000 | ¥286,000 | ¥412,000 |
| Interest Expense | ¥204,000 | ¥1,258,000 | ¥249,000 | ¥204,000 |
| Depreciation & Amortization | ¥1,106,000 | ¥1,095,000 | ¥1,082,000 | ¥1,003,000 |
| EBITDA | -¥1,806,000 | ¥787,000 | -¥825,000 | -¥1,574,000 |
| % Margin | -26.7% | 9.3% | -12.4% | -23% |